Research map: Differential Hepatitis B Surface Antigen Glycan Isomer Kinetics Between Tenofovir Alafenamide and Entecavir: Hepatocellular Carcinoma Risk Stratification in Hepatitis B e Antigen‐Positive Patients

Back to the article

Papers in this map

  1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection · Pietro Lampertico · 2017 · 5529 citations · Cited by this paper
  2. A New Model for Hepatitis C Elimination: CDC‐Dispatching Follow‐Up Coordinators Stationed in Hospitals · 2026 · Related
  3. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level · Chien‐Jen Chen · 2006 · 3162 citations · Cited by this paper
  4. Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC · 2026 · Related
  5. Hepatitis B Virus Infection — Natural History and Clinical Consequences · Don Ganem · 2004 · 2381 citations · Cited by this paper
  6. Effectiveness, Safety and Patient‐Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real‐World Evidence From a Prospective Observational Study · 2026 · Related
  7. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study · Patrick Marcellin · 2012 · 1803 citations · Cited by this paper
  8. Enhancing Chronic Hepatitis B and D Management Through a Tailored Mobile Health Application: Real‐World Outcomes From the Adaptation of the NORA App · 2026 · Related
  9. Mechanisms of HBV-induced hepatocellular carcinoma · Massimo Levrero · 2016 · 1095 citations · Cited by this paper
  10. Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United States · 2026 · Related
  11. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection · Tetsuya Hosaka · 2012 · 715 citations · Cited by this paper
  12. Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan · 2026 · Related
  13. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis · Anna Suk-Fong Lok · 2015 · 556 citations · Cited by this paper
  14. Telemedicine for Low‐Barrier Hepatitis C Care in Rural Patients With Substance Use Disorders: Lessons From Taiwan · 2026 · Related
  15. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg · Christine I. Wooddell · 2017 · 499 citations · Cited by this paper
  16. Real‐World Impact of a Simplified ‘Test and Treat’ Strategy for In‐Hospital HCV Micro‐Elimination · 2026 · Related
  17. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound · Jie Wang · 2016 · 459 citations · Cited by this paper
  18. Co‐Administration of Hepatitis C Direct‐Acting Antivirals and Enzyme‐Inducing Antiepileptic Drugs: Real‐World Experience From a Multi‐Centre Case Series · 2026 · Related
  19. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis · Rong Fan · 2020 · 369 citations · Cited by this paper
  20. Hepatitis B Virus Infection and the Risk of Cardiovascular Disease: Findings From the China Kadoorie Biobank · 2026 · Related
  21. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B · Jonggi Choi · 2018 · 290 citations · Cited by this paper
  22. Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients · Tung‐Hung Su · 2016 · 225 citations · Cited by this paper
  23. Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy · Eisuke Murakami · 2015 · 181 citations · Cited by this paper
  24. Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog‐Treated or Untreated Patients During Chronic and Acute Infection · Emily K. Butler · 2018 · 169 citations · Cited by this paper
  25. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B · George Papatheodoridis · 2020 · 108 citations · Cited by this paper
  26. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B · Yao‐Chun Hsu · 2019 · 102 citations · Cited by this paper
  27. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B · George Papatheodoridis · 2020 · 92 citations · Cited by this paper
  28. Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum · Bernd Stadelmayer · 2020 · 88 citations · Cited by this paper
  29. Highly Sensitive Glycan Profiling of Hepatitis B Viral Particles and a Simple Method for Dane Particle Enrichment · Takanori Wagatsuma · 2018 · 24 citations · Cited by this paper
  30. Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment · Maraake Taddese · 2025 · 21 citations · Cited by this paper
  31. O-glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection · Kiyohiko Angata · 2021 · 16 citations · Cited by this paper
  32. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long‐term nucleos(t)ide analogue therapy · Wei‐Fan Hsu · 2017 · 14 citations · Cited by this paper
  33. Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy · Ayato Murata · 2022 · 12 citations · Cited by this paper
  34. Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients · Taiki Okumura · 2023 · 9 citations · Cited by this paper
  35. Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy · Ritsuzo Kozuka · 2024 · 8 citations · Cited by this paper
  36. Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B · Yuji Ikeda · 2024 · 7 citations · Cited by this paper
  37. Serum O-glycosylated HBsAg levels correlate with HBV RNA in HBeAg positive CHB patients during antiviral therapy · Bilian Yao · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)